Mineralys Therapeutics (MLYS) Retained Earnings (2022 - 2026)
Mineralys Therapeutics (MLYS) posted Retained Earnings of -$496.5 million for Q1 2026, down 144.98% sequentially from $1.1 billion in Q4 2025, and down 44.03% YoY from -$887.0 million in Q1 2025.
Mineralys Therapeutics (MLYS) Retained Earnings (2022 - 2026) Analysis & Trends
Mineralys Therapeutics has reported Retained Earnings for 5 years, with the latest figure at -$496.5 million in Q1 2026.
- Quarterly Retained Earnings fell 44.03% year-over-year to -$496.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$496.5 million (down 44.03% YoY) and the FY2025 annual result came in at $1.1 billion, up 123.56% from the prior year.
- Retained Earnings eased to -$496.5 million in Q1 2026 per MLYS's latest filing, from $1.1 billion in the prior quarter.
- Over five years, Retained Earnings peaked at $1.1 billion in Q4 2025 and troughed at -$496.5 million in Q1 2026.
- A 5-year average of $191.5 million and a median of $155.8 million in 2022 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2024 and 2025: Retained Earnings jumped 840.45% in 2024, then tumbled 171.19% in 2025.
- Over 5 years, Retained Earnings stood at -$52.8 million in 2022, then jumped by 792.78% to $365.9 million in 2023, then soared by 34.96% to $493.8 million in 2024, then soared by 123.56% to $1.1 billion in 2025, then plunged by 144.98% to -$496.5 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$496.5 million, $1.1 billion, and $1.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Mineralys Therapeutics | 2.27 Bn | 1.60 Bn | - | 1.29 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.29 Bn |
| Mar 31, 2026 | -496.50 Mn |
| Dec 31, 2025 | 1.10 Bn |
| Sep 30, 2025 | 1.00 Bn |
| Jun 30, 2025 | -388.00 Mn |
| Mar 31, 2025 | -344.73 Mn |
| Dec 31, 2024 | 493.77 Mn |
| Sep 30, 2024 | 490.50 Mn |
| Jun 30, 2024 | -197.23 Mn |
| Mar 31, 2024 | 484.26 Mn |
| Dec 31, 2023 | 365.86 Mn |
| Sep 30, 2023 | 364.33 Mn |
| Jun 30, 2023 | -77.56 Mn |
| Mar 31, 2023 | -65.40 Mn |
| Dec 31, 2022 | -52.81 Mn |